Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Thyroid Neoplasms 3Immunoglobulin Light-chain Amyloidosis 1Differentiated Thyroid Carcinoma 1Breast Neoplasms 1

Interventions

Dexamethasone 38Melphalan 20Bortezomib 18Cyclophosphamide 17Calcium Dobesilate 14Filgrastim 13daratumumab 11Peripheral Blood Stem Cell Transplantation 10pomalidomide 9Lenalidomide 8fludarabine phosphate 7dexamethasone acetate 6Whole-Body Irradiation 6Mycophenolic Acid 6Granulocyte Colony-Stimulating Factor 5Cyclosporine 5venetoclax 4ixazomib 4dexamethasone 21-phosphate 4Thalidomide 4Etoposide 4Busulfan 4auricularum 3Tacrolimus 3Radiotherapy 3Focal Adhesion Protein-Tyrosine Kinases 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoglobulin Light-chain Amyloidosis × Iodine-124 × Clear all
NCT05968846 2024-12-05

Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

University of Tennessee Graduate School of Medicine

Phase 2 Completed
19 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡